Egg al­ler­gy tri­als halt­ed by Aim­mune; At­las clos­es its 13th fund for $450M

A Phase II tri­al for Aim­mune’s drug to treat chil­dren and young adults with egg al­ler­gies has been ter­mi­nat­ed.

The tri­al was ter­mi­nat­ed on Feb. 28, ac­cord­ing to its clin­i­cal­tri­als.gov site. In an emailed state­ment to End­points News, a com­pa­ny spokesper­son said:

“Aim­mune made the de­ci­sion to ter­mi­nate the study of AR201 in a char­ac­ter­ized oral de­sen­si­ti­za­tion im­munother­a­py (CODIT™) reg­i­men in hen egg-al­ler­gic sub­jects aged 4 to 26 years, in­clu­sive, based on dif­fi­cul­ties in meet­ing en­roll­ment goals, es­pe­cial­ly dur­ing the COVID-19 pan­dem­ic, and not for rea­sons re­lat­ing to any con­cerns re­gard­ing qual­i­ty, safe­ty, or ef­fi­ca­cy.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER